Zobrazeno 1 - 10
of 69
pro vyhledávání: '"CGRP mAbs"'
Autor:
Prakit Anukoolwittaya, Akarin Hiransuthikul, Thanakit Pongpitakmetha, Sekh Thanprasertsuk, Wanakorn Rattanawong
Publikováno v:
The Journal of Headache and Pain, Vol 25, Iss 1, Pp 1-11 (2024)
Abstract Background Most real-world data on CGRP mAbs have been published from high-income countries such as the USA, Western countries, Japan, Korea, and Singapore. However, data from low- and middle-income countries in Southeast Asia is lacking. Th
Externí odkaz:
https://doaj.org/article/8e64752ba0164aa29ab5d17aa93586a1
Publikováno v:
The Journal of Headache and Pain, Vol 25, Iss 1, Pp 1-16 (2024)
Abstract Background Migraine is a highly prevalent neurological disease with a substantial societal burden due to lost productivity. From a societal perspective, we assessed the cost-effectiveness of eptinezumab for the preventive treatment of migrai
Externí odkaz:
https://doaj.org/article/fca3cd0fb19d4594a041cd2b7b168b47
Autor:
Taoufik Alsaadi, Reem Suliman, Vanessa Santos, Ibrahim Al Qaisi, Princess Carmina, Batool Aldaher, Shadi Haddad, Yazan Bader
Publikováno v:
Neurology and Therapy, Vol 13, Iss 2, Pp 465-473 (2024)
Abstract Introduction The introduction of clacitonin gene-related peptide (CGRP) monoclonal antibodies (mAbs) has revolutionized the treatment of migraines. In clinical practice gepants might be considered as a valid option to treat acute attacks in
Externí odkaz:
https://doaj.org/article/5a5d294c06a149ed8eaeedc5afe616a2
Publikováno v:
The Journal of Headache and Pain, Vol 25, Iss 1, Pp 1-13 (2024)
Abstract Background Clinical characteristics and treatment practice of patients with migraine in Japan in real-world setting have not been fully investigated. We conducted a retrospective cohort study using claims database to understand the clinical
Externí odkaz:
https://doaj.org/article/89da59081f1c4026bda12b1e8cd48324
Publikováno v:
Brain Sciences, Vol 14, Iss 9, p 948 (2024)
Background: The advent of monoclonal antibodies (mAbs) targeting the calcitonin gene-related peptide (CGRP) pathway has transformed the management of migraine, offering newfound optimism for clinicians and individuals with episodic migraine (EM) and
Externí odkaz:
https://doaj.org/article/d0fc307d3d21459dbe8b4030316997ca
Autor:
Piero Barbanti, Bianca Orlando, Gabriella Egeo, Florindo d’Onofrio, Alberto Doretti, Stefano Messina, Massimo Autunno, Roberta Messina, Massimo Filippi, Giulia Fiorentini, Cristina Rotondi, Stefano Bonassi, Cinzia Aurilia
Publikováno v:
Brain Sciences, Vol 14, Iss 7, p 672 (2024)
We conducted a multicenter, prospective study (EMBRACE) evaluating the real-life effectiveness, safety, and tolerability of eptinezumab (100 mg/300 mg)—a monoclonal antibody targeting the calcitonin-gene-related peptide (anti-CGRP mAb)—in high-fr
Externí odkaz:
https://doaj.org/article/26eb09c512a54deab40567391b3b856f
Publikováno v:
BMC Neurology, Vol 23, Iss 1, Pp 1-11 (2023)
Abstract Background Calcitonin gene-related peptide (CGRP) monoclonal antibodies (mAbs) are approved in Europe as preventive treatment of migraine in patients with at least four monthly migraine days. Migraine gives rise to direct healthcare expendit
Externí odkaz:
https://doaj.org/article/e7a803784ad3423190d2dc5277b9c471
Akademický článek
Tento výsledek nelze pro nepřihlášené uživatele zobrazit.
K zobrazení výsledku je třeba se přihlásit.
K zobrazení výsledku je třeba se přihlásit.
Akademický článek
Tento výsledek nelze pro nepřihlášené uživatele zobrazit.
K zobrazení výsledku je třeba se přihlásit.
K zobrazení výsledku je třeba se přihlásit.
Akademický článek
Tento výsledek nelze pro nepřihlášené uživatele zobrazit.
K zobrazení výsledku je třeba se přihlásit.
K zobrazení výsledku je třeba se přihlásit.